You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study

 

Online download statistics by month:

Online download statistics by month: March 2021 to July 2025

AbstractFullPdf
Mar 2021386386174
Apr 202110710756
May 2021777736
Jun 202117417437
Jul 2021929220
Aug 202110010017
Sep 2021717125
Oct 2021787844
Nov 202111311343
Dec 202110610735
Jan 2022676944
Feb 202210810844
Mar 2022606230
Apr 2022707742
May 2022667134
Jun 2022717137
Jul 2022464816
Aug 2022515124
Sep 2022606251
Oct 2022747534
Nov 2022475133
Dec 2022363618
Jan 2023555728
Feb 2023767628
Mar 2023313248
Apr 2023191919
May 2023282820
Jun 202324258
Jul 2023272725
Aug 2023393913
Sep 202326265
Oct 2023353622
Nov 202326269
Dec 2023383826
Jan 2024363711
Feb 2024343527
Mar 2024414162
Apr 2024383829
May 2024313229
Jun 2024363522
Jul 2024454623
Aug 2024363232
Sep 2024414124
Oct 2024444437
Nov 2024626527
Dec 2024777826
Jan 2025474727
Feb 2025606132
Mar 2025606035
Apr 2025707150
May 2025424538
Jun 2025232319
Jul 2025110
Total330833471695